Posts by Sandra Ansanay-Alex
Investors and Innovators Connect
Unlock New Opportunities in the Swiss Health Valley A tailor-made B2B event designed to help your company find strategic partners and investment opportunities in the Swiss Health Valley. How BioAlps Supports Your Growth BioAlps facilitates connections between companies, science parks, and research centres with potential partners, investors, or researchers interested in their projects and…
Read MoreBioAlps Deep Dive
An insightful conference or workshop on a life sciences topic Deep Dive events can take the form of conferences or workshops, with a theme on innovation, business development and services in the Health Valley. The theme is defined by an organization in the region that wishes to showcase its expertise and bring together experts on a…
Read MoreBioAlps INSIDE (4à6)
Exclusive visits and presentations of Western Switzerland life sciences companies, followed by a networking apero. Since 2010, BioAlps, in collaboration with the representatives of the economic development agencies of the 7 Western Switzerland cantons, has been organizing visits of companies, science parks and research centers. The event is intended to highlight the know-how and innovative facilities of the…
Read MoreFerring and PharmaBiome enter into a new microbiome R&D collaboration and exclusive licensing agreement
Collaboration leverages the proven development and commercial capability of Ferring with PharmaBiome’s compelling technology to research, develop and manufacture novel donor-independent microbiome-based therapies Ferring Pharmaceuticals and Zürich-based microbiome translation company PharmaBiome are announcing a research & development collaboration to drive forward new microbiome-based biotherapeutics in the field of gastroenterology. The deal provides…
Read MoreThe Swiss HealthTech Center in Biel
Thanks to its location, diverse culture, extensive experience and infrastructure, Switzerland Innovation Park Biel/Bienne (SIPBB) is the perfect platform to support startups in their early stages of development, as well as companies already well established in the market. Developing health related technologies is one of the key competencies of the Swiss HealthTech Center. …
Read More4 life sciences projects supported by the FIF
Four Geneva-based technology projects have won funding from the Fongit Innovation Fund (FIF) for their innovations. A seed loan of CHF 100,000 has been granted to Carrat Sàrl. Three grants of CHF 50,000 have been awarded to each of the following: iSleep, LaxiPed and Pneumoscope. Seed loan of CHF 100,000 awarded to Carrat…
Read MoreASPIVIX receives CE Mark approval for Carevix™
ASPIVIX, announced that carevix™, its novel Cervical Stabilizer, has attained CE marking. This next generation medtech device for routine procedures in gynecology will allow millions of women across Europe access to significantly less painful treatments and IUD insertions. Carevix™ is a cervical stabilizer that uses a gentle approach to minimize pain and bleeding…
Read MoreAlzheimer Research: Gliapharm raises CHF 3.65 Million
The Alzheimer’s Drug Discovery Foundation (ADDF) invests CHF 3.64 Million in GliaPharm to advance its lead programme to accelerate the development of GliaPharm’s new drug, with the aim to gain approval for clinical testing in Alzheimer’s disease. GliaPharm SA, a biotech company that specializes in the research and development of novel therapies to…
Read MoreAesyra raises CHF 2.6 Million
The Vaud-based and EPFL spin-off develops oral appliances preventing sleep bruxism and sleep apnea. The seed financing round was led by Supermoon Capital (USA), the world’s first fund focused on sleep technologies, and high-tech investor Creadd Ventures (Switzerland), with the participation of existing investor Zürcher Kantonalbank. The new financing will support the development…
Read MoreVandria Announces a CHF 18 Million Fundraising
The $20.6M (CHF 18M) round was led by ND Capital together with a small syndicate of HNW private investors. The Vaud-based start-up develops mitophagy inducers that rejuvenate cells to treat age-related and chronic diseases Vandria was spun out of Amazentis SA in 2021 with backing by ND Capital to develop first-in-class small molecule mitophagy…
Read More